Startup hC Bioscience emerges with $24M to join pursuit of transfer RNA therapies
New startup hC Bioscience is developing therapies based on transfer RNA, molecules that can be leveraged to address disease-causing proteins. The biotech joins several companies that are developing tRNA therapies in this emerging class of genetic medicines.
United Kingdom United States Christopher Ahern Tevard Biosciences Leslie Williams Nature Communications
Source: medcitynews.com